Nilutamide
Brand names,
Nilutamide
Analogs
Nilutamide
Brand Names Mixture
Nilutamide
Chemical_Formula
C12H10F3N3O4
Nilutamide
RX_link
http://www.rxlist.com/cgi/generic2/nilutam.htm
Nilutamide
fda sheet
Nilutamide
msds (material safety sheet)
Nilutamide
Synthesis Reference
No information avaliable
Nilutamide
Molecular Weight
317.221 g/mol
Nilutamide
Melting Point
No information avaliable
Nilutamide
H2O Solubility
No information avaliable
Nilutamide
State
Solid
Nilutamide
LogP
2.232
Nilutamide
Dosage Forms
Tablet
Nilutamide
Indication
For use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2)
Nilutamide
Pharmacology
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Nilutamide
Absorption
Rapidly and completely absorbed, yielding high and persistent plasma concentrations.
Nilutamide
side effects and Toxicity
Symptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.
Nilutamide
Patient Information
Patients should be informed that NILANDRON tablets should be started on the day of, or on the day after, surgical
castration. They should also be informed that they should not interrupt their dosing of NILANDRON or stop taking this
medication without consulting their physician.
Because of the possibility of interstitial pneumonitis, patients should also be told to report immediately any
dyspnea or aggravation of pre-existing dyspnea.
Because of the possibility of hepatitis, patients should be told to consult with their physician should nausea,
vomiting, abdominal pain, or jaundice occur.
Because of the possibility of an intolerance to alcohol (facial flushes, malaise, hypotension) following ingestion of
NILANDRON, it is recommended that intake of alcoholic beverages be avoided by patients who experience this reaction.
This effect has been reported in about 5% of patients treated with NILANDRON.
In clinical trials, 13% to 57% of patients receiving NILANDRON reported a delay in adaptation to dark,
ranging from seconds to a few minutes, when passing from a lighted area to a dark area. This effect sometimes does
not abate as drug treatment is continued. Patients who experience this effect should be cautioned about driving at
night or through tunnels. This effect can be alleviated by the wearing of tinted glasses.
Nilutamide
Organisms Affected
Humans and other mammals